HIV neutralizing antibodies: development and association with HIV related disease.

Serum neutralization was measured in 72 sera collected during a 5.5-year period from 10 HIV infected individuals. Neutralizing antibodies (NA) were present in all sera. NA titers ranging from greater than 40 to greater than 640 were detected in sera from 4 patients, who all remained healthy and further an increase with time of NA was observed in these 4 patients. Progression to disease was observed in 3 persons with NA titers less than or equal to 40 who also lacked or lost anti-gag antibodies. Two of these patients were HIV antigenaemic prior to development of disease, whereas antigen was not detected in the remaining 7 healthy persons. A weak positive correlation (R(S) = +0.643, p less than 0.001) was found between titers of NA and whole virus antibody (WVA), with the ratios between titers (NA titer/WVA titer) varying a 100-fold. The results suggest that the presence of NA in some cases might be related to a healthy carrier state and that a combination of low titer NA with decline of anti-gag antibodies and/or HIV antigenaemia is associated with progression to clinical disease.

[1]  J. Nielsen,et al.  Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. , 1987, British medical journal.

[2]  S. Weiss,et al.  Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins. , 1987, Clinical and experimental immunology.

[3]  P. Rubinstein,et al.  Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. , 1987, The Journal of infectious diseases.

[4]  M. Robert-Guroff,et al.  HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia. , 1987, Journal of immunology.

[5]  C. Pedersen,et al.  The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. , 1987, AIDS.

[6]  R. Tedder,et al.  HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN TWO COHORTS OF HOMOSEXUAL MEN: NEUTRALISING SERA AND ASSOCIATION OF ANTI-GAG ANTIBODY WITH PROGNOSIS , 1987, The Lancet.

[7]  J. Groopman,et al.  Characterization of Serum Netralization Response to the Human Immunodeficiency Virus (HIV) , 1987 .

[8]  U. Bienzle,et al.  Neutralizing antibodies and the course of HIV-induced disease. , 1987, AIDS research and human retroviruses.

[9]  C. Petersen,et al.  The immunological and clinical outcome of HIV infection: 31 months of follow-up in a cohort of homosexual men. , 1987, Scandinavian journal of infectious diseases.

[10]  J. Nielsen,et al.  Antibody to HIV in patients with acute hepatitis B in the period 1975-1984. , 1987, Scandinavian journal of infectious diseases.

[11]  A. Dalgleish,et al.  Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.

[12]  J. Goudsmit,et al.  Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. , 1986, British medical journal.

[13]  S. Hammer,et al.  ISOLATION OF HUMAN IMMUNODEFICIENCY VIRUS AND SERUM NEUTRALISING ANTIBODY , 1986, The Lancet.

[14]  L. Arthur,et al.  Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Nakamura,et al.  Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. , 1986, Science.

[16]  S. Wain-Hobson,et al.  Genetic variability of the AIDS virus: Nucleotide sequence analysis of two isolates from African patients , 1986, Cell.

[17]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[18]  N. Grunnet,et al.  HTLV‐III Antibody Testing in Three Danish Blood Banks , 1986, Vox sanguinis.

[19]  D. Jeffries,et al.  THREE-YEAR PROSPECTIVE STUDY OF HTLV-III/LAV INFECTION IN HOMOSEXUAL MEN , 1986, The Lancet.

[20]  Susan E. Wilson,et al.  Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. , 1986, Science.

[21]  D. Francis,et al.  The prospects for and pathways toward a vaccine for AIDS. , 1985, The New England journal of medicine.

[22]  M. Robert-Guroff,et al.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.

[23]  Robin A. Weiss,et al.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.

[24]  H. Joller,et al.  Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. , 1985, The New England journal of medicine.

[25]  D. Francis,et al.  Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). , 1985, Journal of immunological methods.

[26]  John D. Minna,et al.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma , 1980, Proceedings of the National Academy of Sciences.

[27]  N. B. Atkin,et al.  Interpretation of changes in the uterine cervix. , 1969, Lancet.

[28]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .